Silo pharma enters joint development agreement for sp-26 ketamine implant device targeting pain management

Prototype development and feasibility testing underway for optimized subcutaneous delivery sarasota, fl, nov. 29, 2024 (globe newswire) -- silo pharma, inc. (nasdaq: silo) (“silo” or the “company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced a collaboration agreement with kymanox for specialized design and development of a subcutaneous insertion device for sp-26, the company's ketamine-loaded implant therapeutic targeting fibromyalgia and chronic pain. under terms of the agreement, kymanox will conduct an initial proof-of-concept design phase followed by full system prototype and feasibility testing to determine optimal insertion depth in tissue.
SILO Ratings Summary
SILO Quant Ranking